Dr Kumar Prabhash's commentary: Gefitinib vs. Gefitinib plus Pemetrexed and Carboplatin chemotherapy in EGFR-Mutated lung cancer
M3 India Newsdesk Aug 20, 2019
A clinical study by Dr. Kumar Prabhash and his team was published in JCO in the month of August 2019 which concluded that adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.
This was a phase III randomised trial in patients with advanced NSCLC harboring an EGFR-sensitising mutation and a performance status of 0 to 2.
1. TKI with chemotherapy improves outcome in EGFR Mutation lung cancer patients
2. This combination doubles the disease control
3. This is a new standard treatment option for these patients
4. We have potential to develop effective treatment for patients in our country
Dr Kumar Prabhash's commentry
In EGFR mutation positive lung cancer TKI is better than chemotherapy. This study shows that the disease can be controlled better with TKI and chemotherapy as compared with TKI alone. At present other options which control the disease with similar effect is TKI (osimertinib).
We know that osimertinib works in second line setting also.This brings the discussion of appropriate sequencing of treatment in clinic.Due to cost implication only less than 5% patients can take this drug (osimertinib).
As compared this combination used in this study can be used by almost any patient in our country. This highlights the development of treatment in the country which is as effective as the treatment which is very costly and only 5% of patients can take it.
To access the original article abstract click this link: https://ascopubs.org/doi/full/10.1200/JCO.19.01154
M3 India is hosting a Live Webinar with Dr Kumar Prabhash on 31st August 2019.
Click here to register and get a chance to have your questions answered by the expert himself.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitionsTry M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor